CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	2.65M 2.29M 2.14M 1.96M 3.71M 253M 3.76M 25.18M 9.86M 126M 9.94M 9.72M 416M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.5M 21.21M 19.76M 18.15M 34.32M 2.34B 34.76M 233M 91.28M 1.16B 92.01M 89.99M 3.85B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	2025-07-20
Kun Qian DFI	Director of Finance/CFO	44	2025-05-15
Chun Hua Wang COO	Chief Operating Officer	54	2016-12-31

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	2013-03-31
Zhen Bo Su BRD	Director/Board Member	50	2023-03-20
Thomas Folinsbee BRD	Director/Board Member	59	2023-03-20

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news : ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.53%	-3.95%	+50.70%	+153.56%	1,024B
JOHNSON & JOHNSON	+0.21%	-2.68%	+53.20%	+51.79%	618B
ABBVIE INC.	-2.51%	-3.25%	+28.54%	+68.94%	443B
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+30.67%	349B
ASTRAZENECA PLC	-0.69%	-0.30%	+13.76%	+12.83%	264B
NOVO NORDISK A/S	-7.37%	-4.40%	-0.74%	-44.28%	209B
AMGEN INC.	-0.64%	+2.43%	+29.74%	+65.93%	208B
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.05%	+72.05%	162B
PFIZER INC.	+0.40%	+1.92%	+6.47%	-29.77%	143B
Average	-1.32%	-1.21%	+26.03%	+42.41%	379.88B
Weighted average by Cap.	-1.00%	-2.02%	+36.14%	+71.90%

	2024	2025
Net sales	28.54M 24.71M 23.02M 21.14M 39.98M 2.72B 40.49M 271M 106M 1.35B 107M 105M 4.48B	20.71M 17.93M 16.71M 15.35M 29.02M 1.98B 29.39M 197M 77.16M 983M 77.78M 76.07M 3.25B
Net income	-39.26M -33.99M -31.66M -29.09M -55M -3.74B -55.7M -373M -146M -1.86B -147M -144M -6.17B	-48.06M -41.61M -38.76M -35.61M -67.32M -4.58B -68.19M -457M -179M -2.28B -180M -177M -7.55B
Net Debt	6.05M 5.24M 4.88M 4.48M 8.48M 577M 8.58M 57.53M 22.54M 287M 22.72M 22.22M 951M	21.85M 18.92M 17.63M 16.19M 30.62M 2.08B 31.01M 208M 81.42M 1.04B 82.07M 80.27M 3.43B

End-of-day quote Nasdaq Other stock markets
- ^USD	-